These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 4004990)

  • 1. Effect of bezafibrate during 4.5 years of treatment of hyperlipoproteinaemia.
    Olsson AG; Lang PD; Vollmar J
    Atherosclerosis; 1985 May; 55(2):195-203. PubMed ID: 4004990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of bezafibrate therapy on serum and lipoprotein lipids].
    Romics L; Németh Csóka M; Szám I; Pados G; Karádi I; Köszegi G; Kusztos R
    Orv Hetil; 1986 Oct; 127(40):2425-8, 2431. PubMed ID: 3537905
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein levels in patients with hyperlipoproteinemia type II and IV].
    Bednarska-Makaruk M; Kuźmińska A; Chotkowska E; Kurjata P; Polakowska M; Broda G; Rywik S
    Pol Arch Med Wewn; 1992 Mar; 87(3):149-56. PubMed ID: 1523145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevation of high density lipoprotein cholesterol (cHDL) and reduction of the total cholesterol/cHDL index in the treatment of hyperlipoproteinaemias IIb and IV with bezafibrate.
    Neuman MP; Kurlat MI; Neuman J
    Curr Med Res Opin; 1983; 8(5):358-67. PubMed ID: 6839800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate].
    Schiffl H; Weidmann P; Fragiacomo C; Noseda G; Bachmann C
    Schweiz Med Wochenschr; 1985 Jun; 115(26):907-11. PubMed ID: 3927481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of apoproteins A and B, lipoproteins and plasma lipids during treatment with bezafibrate in various forms of hyperlipoproteinemia].
    Saitta A; Bonaiuto M; Lanzafame F; Mileto A; Pernice F; Cinquegrani M; Mazza G; Micali G; Pangallo A; Fodale P
    Clin Ter; 1988 Mar; 124(5):373-81. PubMed ID: 2974348
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of etofibrate retard, bezafibrate and procetofen.
    Luley C; Schwartzkopff W; Schilling A; Calder D; Scheffler W
    Artery; 1980; 8(2):128-33. PubMed ID: 7458677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment of severe familial hypercholesterolemia in children: effect of sitosterol and bezafibrate.
    Becker M; Staab D; Von Bergman K
    Pediatrics; 1992 Jan; 89(1):138-42. PubMed ID: 1727999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenofibrate therapy of hypertriglyceridaemia. Differential effects on LDL cholesterol level in type IV and in type IIb primary hyperlipoproteinaemia.
    Sommariva D; Bonfiglioli D; Pogliaghi I; Ottomano C; Fasoli A
    Eur J Clin Pharmacol; 1984; 26(6):741-4. PubMed ID: 6489413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
    Leitersdorf E; Muratti EN; Eliav O; Peters TK
    Am J Cardiol; 1995 Jul; 76(2):84A-88A. PubMed ID: 7604807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
    Durrington PN; Mackness MI; Bhatnagar D; Julier K; Prais H; Arrol S; Morgan J; Wood GN
    Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of bezafibrate on lipoprotein lipids and apolipoproteins B and A1 in patients with primary hypercholesterolemia].
    Branchi A; Sommariva D; Tirrito M; Bonfiglioli D; Pini C; Scandiani L; Orlandi S; Fasoli A
    Clin Ter; 1987 Jul; 122(1):17-23. PubMed ID: 2973892
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia.
    Betteridge DJ; O'Bryan-Tear CG
    Postgrad Med J; 1996 Dec; 72(854):739-43. PubMed ID: 9015467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of bezafibrate and colestipol on LDL-cholesterol, LDL-apolipoprotein B and HDL-cholesterol in hyperlipoproteinaemia.
    Kłosiewicz-Latoszek L; Nowicka G; Szostak WB; Naruszewicz M
    Atherosclerosis; 1987 Feb; 63(2-3):203-9. PubMed ID: 3827981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
    Saku K; Sasaki J; Arakawa K
    Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind comparison of bezafibrate versus placebo in male volunteers with hyperlipoproteinemia.
    Bradford RH; Goldberg AC; Schonfeld G; Knopp RH
    Atherosclerosis; 1992 Jan; 92(1):31-40. PubMed ID: 1575820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination.
    Leitersdorf E; Muratti EN; Eliav O; Meiner V; Eisenberg S; Dann EJ; Sehayek E; Peters TK; Stein Y
    Am J Med; 1994 May; 96(5):401-7. PubMed ID: 8192170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein B levels in patients with type II and IV hyperlipoproteinemia].
    Sznajderman M
    Pol Arch Med Wewn; 1983; 70(5-6):259-69. PubMed ID: 6677890
    [No Abstract]   [Full Text] [Related]  

  • 20. Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients.
    Franceschini G; Sirtori M; Gianfranceschi G; Frosi T; Montanari G; Sirtori CR
    Artery; 1985; 12(6):363-81. PubMed ID: 4051756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.